Sugi Predict

Sugi Predict / Compounds / SCHEMBL503470

SCHEMBL503470

SCHEMBL503470

O=C(O)[C@H](O)c1ccc(Br)cc1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.62
▸ MAPK1 P28482 1/20 0.62
▸ LDHA P00338 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ FPR2 P25090 1/20 0.43
▸ BLM P54132 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ CES2 O00748 1/20 0.42
▸ CES1 P23141 1/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ CNR1 P21554 2/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ CYP2C19 P33261 1/20 0.41
▸ ALOX5 P09917 1/20 0.41
▸ CNR2 P34972 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29903941 1.00 LMNA (0.62) LMNAMAPK1LDHACYP1A2FPR2
SCHEMBL10170603 1.00 LMNA (0.62) LMNAMAPK1LDHACYP1A2FPR2
SCHEMBL323295 1.00 LMNA (0.62) LMNAMAPK1LDHACYP1A2FPR2
SCHEMBL8997394 0.94 LMNA (0.56) LMNAMAPK1LDHACYP1A2FPR2
SCHEMBL275597 0.87 LMNA (0.79) LMNAMAPK1BLMNPSR1TSHR
SCHEMBL25309981 0.79 MEN1 (0.49) LMNAMAPK1CYP1A2CES2CES1
SCHEMBL5778110 0.79 CYP1A2 (0.55) CYP1A2CES2CES1CNR1SMN1; SMN2
SCHEMBL14215891 0.79 HPGD (0.48) LMNAMAPK1LDHACYP1A2KMT2A
SCHEMBL467741 0.78 LMNA (0.65) LMNAMAPK1BLMNPSR1TSHR
SCHEMBL20930835 0.78 CYP2D6 (0.61) LDHACYP1A2FPR2CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220325035-A1 POLYESTER, POLYESTERAMIDE, AND POLYAMIDE COMPOSITIONS IYER ANANTH V (US) 2022-10-13 — — US claimed
CN-105085244-A Preparing method of (R)-(+)-4-bromomandelic acid PENG JING 2015-11-25 — — CN claimed
WO-2003103579-A2 HIGH-THROUGHPUT METHODS AND SYSTEMS FOR SCREENING OF COMPOUNDS TO TREAT/PREVENT KIDNEY DISORDERS TRANSFORM PHARMACEUTICALS, INC. (US) 2003-12-18 — — WO claimed
EP-1124417-A2 COMPOSITIONS COMPRISING PLANT CELL GROWTH REGULATING COMPOUNDS AND METHODS OF USE THEREOF INVITROGEN CORPORATION (US) 2001-08-22 — — EP claimed
WO-2000024249-A2 COMPOSITIONS COMPRISING PLANT CELL GROWTH REGULATING COMPOUNDS AND METHODS OF USE THEREOF INVITROGEN CORPORATION (US) 2000-05-04 — — WO claimed
US-5683793-A Ink jet transparencies XEROX CORPORATION (US) 1997-11-04 — — US claimed
US-5589277-A INK JET PRINTING, AQUEOUS INKS, FAST DRYING XEROX CORPORATION (US) 1996-12-31 — — US claimed
US-20260125363-A1 PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2026-05-07 — — US disclosed
US-12415798-B2 Processes for making modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-09-16 — — US disclosed
CN-120005420-A Disperse dye for superfine denier fiber and synthesis method thereof 青岛大学 2025-05-16 — — CN disclosed
CN-113355367-B Application of ketoacid reductase in synthesis of chiral aromatic 2-hydroxy acid 浙江工业大学 2024-03-26 — — CN disclosed
CN-111757874-B Methods for preparing modulators of cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2024-03-08 — — CN disclosed
US-20240025877-A1 PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED 2024-01-25 — — US disclosed
US-6239152-B1 Oxazolidinone combinatorial libraries, compositions and methods of preparation PHARMACIA & UPJOHN COMPANY 2001-05-29 — — US disclosed
WO-2001016093-A1 SUBSTITUTED α-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF CYTOVIA, INC. (US) 2001-03-08 — — WO disclosed
US-6162417-A Pyrrolo isoquinolines EMORY UNIVERSITY (US) 2000-12-19 — — US disclosed
WO-2000024249-A2 COMPOSITIONS COMPRISING PLANT CELL GROWTH REGULATING COMPOUNDS AND METHODS OF USE THEREOF INVITROGEN CORPORATION (US) 2000-05-04 — — WO disclosed
EP-0623120-A1 PIPERIDINEACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION GLAXO GROUP LIMITED (GB) 1994-11-09 — — EP disclosed
WO-1993014077-A1 PIPERIDINEACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION GLAXO GROUP LIMITED (GB) 1993-07-22 — — WO disclosed
US-4218380-A OXIDATION OF THE A-HYDROXY-ARYLACETIC ACID BAYER AKTIENGESELLSCHAFT (DE) 1980-08-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125363-A1 PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SLC26A4, SLC26A3 LMNA 1827/4885MAPK1 366/4885LDHA 4782/4885
US-20240025877-A1 PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1B, SCNN1G LMNA 3445/4885MAPK1 2625/4885LDHA 3374/4885
US-12415798-B2 Processes for making modulators of cystic fibrosis transmembrane conductance regulator CFTR, SCNN1B, SCNN1G LMNA 3445/4885MAPK1 2625/4885LDHA 3374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.